SCYNEXIS Raises $40 Million in Strategic Private Placement

SCYNEXIS ( (SCYX) ) has shared an announcement.

On March 30, 2026, SCYNEXIS agreed to raise approximately $40 million in gross proceeds through a private placement of 34.75 million common shares, 8.75 million pre-funded warrants and 43.5 million common warrants to new and existing institutional investors, including a small participation by its CEO. The deal, expected to close around April 1, 2026, could bring in up to an additional $52.2 million if warrants are fully exercised, extends the company’s projected cash runway into mid-2029, and includes registration rights and a commitment to seek shareholder approval for an increase in authorized shares.

The securities were sold in a non-registered offering relying on private placement exemptions, with Guggenheim Securities acting as sole placement agent, and the common warrants’ exercisability tied both to shareholder approval and clinical milestones for SCY-770 in ADPKD. The financing, backed by several specialist healthcare investors, strengthens SCYNEXIS’s balance sheet and supports ongoing development of its rare-disease and antifungal programs, potentially improving its strategic position in the biotech sector.

The most recent analyst rating on (SCYX) stock is a Hold with a $0.90 price target. To see the full list of analyst forecasts on SCYNEXIS stock, see the SCYX Stock Forecast page.

Spark’s Take on SCYX Stock

According to Spark, TipRanks’ AI Analyst, SCYX is a Neutral.

The score is held back primarily by inconsistent and currently loss-making financial performance (negative margins and negative free cash flow). The strengthened, low-leverage balance sheet is the main offsetting positive, while technical indicators are neutral-to-slightly positive and valuation is constrained by negative earnings and no dividend support.

To see Spark’s full report on SCYX stock, click here.

More about SCYNEXIS

SCYNEXIS, Inc. is a biotechnology company focused on developing innovative therapies for severe rare diseases, including SCY-770 for Autosomal Dominant Polycystic Kidney Disease, which has Orphan Drug designation. The company also owns the proprietary antifungal “fungerps” platform, including approved drug BREXAFEMME, licensed to GSK, and clinical-stage candidate SCY-247.

Average Trading Volume: 376,882

Technical Sentiment Signal: Sell

Current Market Cap: $35.27M

Find detailed analytics on SCYX stock on TipRanks’ Stock Analysis page.